C
Christophe Caux
Researcher at French Institute of Health and Medical Research
Publications - 254
Citations - 32907
Christophe Caux is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Immune system & Dendritic cell. The author has an hindex of 74, co-authored 232 publications receiving 30760 citations. Previous affiliations of Christophe Caux include Centre national de la recherche scientifique & International Facility Management Association.
Papers
More filters
Patent
In vitro generation of human dendritic cells
TL;DR: In this paper, a method for generating human dendritic cells in vitro by treating CD34+ cells with tumor necrosis factor-α and interleukin-3 or with GM-CSF was provided.
Book ChapterDOI
Characterization of Human CD34+ Derived Dendritic/Langerhans Cells (D-Lc)
Christophe Caux,Béatrice Vanbervliet,Catherine Massacrier,Bertrand Dubois,Colette Dezutter-Dambuyant,Daniel Schmitt,Jacques Banchereau +6 more
TL;DR: These in vitro generated dendritic/ Langerhans cells (D-Lc) are very potent in priming naive T cells and in capturing, processing and presenting solubleantigen to antigen-specific T cell clones.
Journal ArticleDOI
Repurposing infectious disease vaccines for intratumoral immunotherapy.
Ignacio Melero,Maria Gato,Tala Shekarian,Angela Aznar,Sandrine Valsesia-Wittmann,Christophe Caux,Iñaki Etxeberrria,Alvaro Teijeira,Aurélien Marabelle +8 more
TL;DR: Results highlight that intratumoral anti-infectious vaccines can turn cold tumors into hot, and underscore the key role played by virus-induced type I interferon pathways to overcome resistance to immune checkpoint-targeted antibodies.
Journal ArticleDOI
Neoepitopes-based vaccines: challenges and perspectives
Vincent Alcazer,Paola Bonaventura,Laurie Tonon,Sandrine Wittmann,Christophe Caux,Stéphane Depil,Stéphane Depil +6 more
TL;DR: Although studies have focused on mutated epitopes corresponding to single nucleotide variants, other neoantigens could be of strong interest such as those linked to tumour specific RNA-splicing abnormalities or associated with insertions-deletions.
Journal ArticleDOI
MAVS deficiency induces gut dysbiotic microbiota conferring a proallergic phenotype
Emilie Plantamura,Amiran Dzutsev,Amiran Dzutsev,Mathias Chamaillard,Sophia Djebali,Lyvia Moudombi,Lilia Boucinha,Morgan Grau,Claire Macari,David Bauché,David Bauché,Oana Dumitrescu,Jean-Philippe Rasigade,Saskia Lippens,Michelina Plateroti,Elsa Kress,Annabelle Cesaro,Clovis Bondu,Ulrike Rothermel,Mathias Heikenwalder,Gerard Lina,Azzak Bentaher-Belaaouaj,Julien C. Marie,Julien C. Marie,Christophe Caux,Giorgio Trinchieri,Jacqueline Marvel,Marie-Cécile Michallet +27 more
TL;DR: Results indicate that manipulating the gut microbiota may help in the development of therapeutic strategies for the treatment of human allergic skin pathologies, and highlight an unexpected role of the RIG-I–MAVS pathway in maintenance of intestinal barrier function and modulation of gut commensal flora to prevent theDevelopment of inflammatory diseases such as allergy.